Literature DB >> 18977851

Bevacizumab-associated osteonecrosis of the jaw.

S Greuter, F Schmid, T Ruhstaller, B Thuerlimann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18977851      PMCID： PMC2733125          DOI： 10.1093/annonc/mdn653

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

1.  Bisphosphonates: new antiangiogenic molecules in cancer treatment?

Authors:  B Vincenzi; D Santini; L Rocci; G Tonini
Journal:  Ann Oncol       Date:  2003-05       Impact factor: 32.976

2.  Osteonecrosis of the jaw related to bevacizumab.

Authors:  Cherry L Estilo; Monica Fornier; Azeez Farooki; Diane Carlson; George Bohle; Joseph M Huryn
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

3.  Distal phalange necrosis: a severe manifestation of palmar plantar erythrodysesthesia.

Authors:  Innocenza Palaia; Roberto Angioli; Filippo Bellati; Stefano Basile; Carla Rabitti; Pierluigi Benedetti Panici
Journal:  Am J Obstet Gynecol       Date:  2006-07-26       Impact factor: 8.661

Review 4.  Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.

Authors:  Sook-Bin Woo; John W Hellstein; John R Kalmar
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

5.  The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies.

Authors:  K J Kim; B Li; K Houck; J Winer; N Ferrara
Journal:  Growth Factors       Date:  1992       Impact factor: 2.511
  5 in total
  16 in total

Review 1.  A systematic review of bisphosphonate osteonecrosis (BON) in cancer.

Authors:  Cesar Augusto Migliorati; Sook-Bin Woo; Ian Hewson; Andrei Barasch; Linda S Elting; Fred K L Spijkervet; Michael T Brennan
Journal:  Support Care Cancer       Date:  2010-04-22       Impact factor: 3.603

Review 2.  Osteochemonecrosis: an overview.

Authors:  John Hellstein
Journal:  Head Neck Pathol       Date:  2014-11-20

3.  Anti-vascular endothelial growth factor antibody monotherapy causes destructive advanced periodontitis in rice rats (Oryzomys palustris).

Authors:  J G Messer; E J Castillo; A M Abraham; J M Jiron; R Israel; J F Yarrow; S Thomas; M C Reynolds; R D Wnek; M Jorgensen; N Wanionok; C Van Poznak; I Bhattacharyya; D B Kimmel; J I Aguirre
Journal:  Bone       Date:  2019-11-07       Impact factor: 4.398

Review 4.  HIF targets in bone remodeling and metastatic disease.

Authors:  Rachelle W Johnson; Ernestina Schipani; Amato J Giaccia
Journal:  Pharmacol Ther       Date:  2015-02-12       Impact factor: 12.310

5.  Does CBCT alter the diagnostic thinking efficacy, management and prognosis of patients with suspected Stage 0 medication-related osteonecrosis of the jaws?

Authors:  Hiroaki Shimamoto; Tristan R Grogan; Tomomi Tsujimoto; Naoya Kakimoto; Shumei Murakami; David Elashoff; Tara L Aghaloo; Sotirios Tetradis
Journal:  Dentomaxillofac Radiol       Date:  2017-12-15       Impact factor: 2.419

Review 6.  Updates on osteonecrosis of the jaw.

Authors:  Junro Yamashita; Laurie K McCauley; Catherine Van Poznak
Journal:  Curr Opin Support Palliat Care       Date:  2010-09       Impact factor: 2.302

7.  Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process.

Authors:  Giordana Bettini; Stella Blandamura; Giorgia Saia; Alberto Bedogni
Journal:  BMJ Case Rep       Date:  2012-10-22

Review 8.  Clinical review: kinase inhibitors: adverse effects related to the endocrine system.

Authors:  Maya B Lodish
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

9.  Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.

Authors:  Ourania Nicolatou-Galitis; Maria Kouri; Erofili Papadopoulou; Emmanouil Vardas; Dimitra Galiti; Joel B Epstein; Sharon Elad; Giuseppina Campisi; Nikolaos Tsoukalas; Kivanc Bektas-Kayhan; Winston Tan; Jean-Jacques Body; Cesar Migliorati; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2018-10-23       Impact factor: 3.603

10.  Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw.

Authors:  Bruno Vincenzi; Andrea Napolitano; Alice Zoccoli; Michele Iuliani; Francesco Pantano; Nicola Papapietro; Vincenzo Denaro; Daniele Santini; Giuseppe Tonini
Journal:  J Hematol Oncol       Date:  2012-09-17       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.